UroGen Pharma Ltd. (NASDAQ: URGN) is a Healthcare company (Biotechnology) with a market capitalization of $1.5B. The Maz Rating grades it against the other companies in its sector.
UroGen Pharma Ltd.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.87, UroGen Pharma Ltd. trades at 5.7x sales. Over the last twelve months it generated about $256M of revenue and a net loss of $66M. It runs a gross margin of 91.4%, an operating margin of -12.4% and a net margin of -26.3%. It shows return on equity of 54.0%, return on invested capital of -15.5% and a free cash flow yield of -9.0%. On the balance sheet: a debt-to-equity ratio of -1.57 and a current ratio of 3.40. Over the past 52 weeks the share price ranged from $16.50 to $50.81, with a beta of 1.64.
UroGen Pharma Ltd. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 12 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.